GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » IMBdx Inc (XKRX:461030) » Definitions » COGS-to-Revenue

IMBdx (XKRX:461030) COGS-to-Revenue : 1.09 (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is IMBdx COGS-to-Revenue?

IMBdx's Cost of Goods Sold for the three months ended in Dec. 2024 was ₩687 Mil. Its Revenue for the three months ended in Dec. 2024 was ₩633 Mil.

IMBdx's COGS to Revenue for the three months ended in Dec. 2024 was 1.09.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. IMBdx's Gross Margin % for the three months ended in Dec. 2024 was -8.50%.


IMBdx COGS-to-Revenue Historical Data

The historical data trend for IMBdx's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IMBdx COGS-to-Revenue Chart

IMBdx Annual Data
Trend Dec21 Dec22 Dec23 Dec24
COGS-to-Revenue
0.97 0.86 0.65 0.74

IMBdx Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.53 0.63 0.58 0.84 1.09

IMBdx COGS-to-Revenue Calculation

IMBdx's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=2518.914 / 3406.965
=0.74

IMBdx's COGS to Revenue for the quarter that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=686.965 / 633.136
=1.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IMBdx  (XKRX:461030) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

IMBdx's Gross Margin % for the three months ended in Dec. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 686.965 / 633.136
=-8.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


IMBdx COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of IMBdx's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


IMBdx Business Description

Traded in Other Exchanges
N/A
Address
131 Gasandigital 1-ro, 21st Floor BYC Highcity Building A, Geumcheon-gu, Seoul, KOR, 08506
IMBdx Inc detects and analyzes the genomic profile of tumor DNA with a single draw of blood. It provides personalized and optimized analysis information that can be utilized in therapy selection and monitoring. Its AlphaLiquid platform offers ctDNA-based precision diagnostics solutions across the full continuum of cancer care, from therapy selection (AlphaLiquid 100/HRR) to recurrence and minimal residual disease(MRD) monitoring (CancerDetect), and multi-cancer early detection (CancerFind). Its services are Clinical Service BioPharma, Research, and Healthcare Checkup.

IMBdx Headlines

No Headlines